Yelena Y. Janjigian, MD, discusses the long-term survival data from the KEYNOTE-811 trial of pembrolizumab plus trastuzumab ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

The trial will include patients with locally advanced or metastatic HER2-positive, PD-L1-positive gastric or gastroesophageal junction cancer.

Yelena Y. Janjigian, MD, discusses the standard approval of pembrolizumab plus trastuzumab and chemotherapy for the treatment ...

Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer ...

Shanghai Henlius Biotech announced that the FDA has granted Orphan Drug Designation for HLX22, an anti-HER2 monoclonal ...

Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...

Stomach cancer rates in the United States have been steadily decreasing for decades, but recent trends reveal an increase in early-onset stomach cancer in people younger than 50, particularly women.

The conversion from accelerated approval to traditional approval was supported by data from the phase 3 KEYNOTE-811 trial.

LUND, SE / ACCESS Newswire / March 20, 2025 /Alligator Bioscience (Nasdaq Stockholm:ATORX) today announces that the U.S. Food ...

Gastric cancer is often diagnosed at an advanced stage, with a poor prognosis and a 5-year relative survival rate of only 6%. Despite significant advancements in targeted therapies, such as anti-HER2 ...

[5] Guan, WL.,et al. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol 16, 57 (2023). [6] Jin Li et al., HLX22 plus HLX02 and XELOX for first-line treatment of ...